PureTech Founded Entity Gelesis Announces its Proprietary Superabsorbent Hydrogel Induced Beneficial Changes to the Gut Microbiota and Expanded Akkermansia, a Bacterial Species Associated with Gut Health and Weight Loss, in New StudyBusiness Wire • 04/29/22
PureTech Founded Entity Vedanta Biosciences Publishes Phase 1a/1b Results for Lead Program VE303 in Cell Host & Microbe and Highlights Planned Presentations of Phase 2 VE303 ResultsBusiness Wire • 04/13/22
Vedanta Biosciences Publishes Phase 1a/1b Results for Lead Program VE303 in Cell Host & Microbe and Highlights Planned Presentations of Phase 2 VE303 ResultsBusiness Wire • 04/13/22
PureTech Founded Entity Akili Announces American Journal of Psychiatry Publication of Data Demonstrating its Digital Therapeutic AKL-T03 Improves Cognitive Impairments in Adults w/ Major Depressive Disorder When Combined w/ Antidepressant MedicationBusiness Wire • 04/12/22
PureTech Announces Publication of Research from Collaborators Demonstrating PureTech's Glyph™ Platform Enhances Oral Absorption of Buprenorphine (a Clinically-Validated Opioid Replacement Therapy)Business Wire • 04/12/22
PureTech Founded Entity Akili Appoints Game Industry Veteran Behind Bejeweled, Plants vs. Zombies as Chief Product OfficerBusiness Wire • 03/17/22
PureTech Founded Entity Gelesis® Releases Preliminary National Launch Results for Plenity®: Record-Breaking Levels of Prescriptions and Online TrafficBusiness Wire • 03/16/22
PureTech Founded Entity Akili Named to Fast Company's Annual List of the World's 50 Most Innovative Companies for 2022Business Wire • 03/08/22
Vedanta Biosciences to Present at Chardan's 2022 Metagenomics and Microbiome Medicines SummitBusiness Wire • 02/23/22
PureTech Founded Entity Akili Announces PLOS ONE Publication of Clinical Study Results and EEG Data Showing Akili Digital Therapeutic EndeavorRx® Activates Systems in Brain Key to Attentional FunctioningBusiness Wire • 02/17/22
PureTech Founded Entity Akili Interactive Announces Filing of Registration Statement on S-4 in Connection with its Proposed Business Combination with Social Capital Suvretta Holdings Corp. IBusiness Wire • 02/15/22
PureTech to Present at the SVB Leerink 11th Annual Global Healthcare ConferenceBusiness Wire • 02/10/22
PureTech Founded Entity Gelesis to Launch Plenity® National Media Campaign That Challenges Restrictive Dieting NormsBusiness Wire • 01/31/22
Wall Street Analysts Think PureTech Health PLC Sponsored ADR (PRTC) Could Surge 92%: Read This Before Placing a BetZacks Investment Research • 01/28/22
PureTech Founded Entity Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. IBusiness Wire • 01/26/22
PureTech Founded Entity Gelesis, the Maker of Plenity® for Weight Management, Will Debut as a Publicly Traded Company Following the Closing of its Business Combination with CapstarBusiness Wire • 01/14/22
Wall Street Analysts Predict an 82% Upside in PureTech Health PLC Sponsored ADR (PRTC): Here's What You Should KnowZacks Investment Research • 01/11/22
PureTech's LYT-100 (Deupirfenidone) Achieves 50% Reduction in Healthy Older Adults Experiencing GI-Related Adverse Events Compared to PirfenidoneBusiness Wire • 01/06/22
PureTech Founded Entity Gelesis Appoints Inogen Co-Founder and Former CFO Ali Bauerlein to Board of Directors and Audit CommitteeBusiness Wire • 01/05/22
PureTech Provides End of Year Report on Key Progress Across Wholly Owned Programs and Founded EntitiesBusiness Wire • 12/16/21
PureTech Presents Preclinical Proof-of-Concept Data for LYT-300 (Oral Allopregnanolone) as Potential Treatment for Neurological and Neuropsychological ConditionsBusiness Wire • 12/08/21
PureTech Advances Wholly-Owned Candidate LYT-300 (Oral Allopregnanolone) into Clinical Study for Potential Treatment of Neurological and Neuropsychological ConditionsBusiness Wire • 12/07/21
